Home Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
 

Keywords :   


Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection

2013-01-07 14:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDAs review to be completed in the first half of 2013. Language:  English Contact HTML:  MerckMedia Contacts:Pam Eisele, 908-423-5042Lainie Keller, 908-423-4187orInvestor Contact:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: application drug acceptance injection

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
06.11Atlantic Tropical Weather Outlook
06.11Tropical Storm Rafael Graphics
06.11Tropical Storm Rafael Public Advisory Number 9A
06.11Summary for Tropical Storm Rafael (AT3/AL182024)
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
More »